AIDS Therapies (Delavirdine)

Anti-HIV Agent DLV Promising in Phase I/II Study

Published in AIDS Weekly, August 5th, 1996

Delavirdine mesylate (DLV), a "potent non-nucleoside reverse transcriptase inhibitor with activity specific for HIV type 1," has appeared safe and well-tolerated even at high doses.

Researchers from the U.S. National Institutes of Allergy and Infectious Diseases (NIAID), Chiron Corporation and Upjohn reported in the July 1996 issue of Antimicrobial Agents and Chemotherapy (Antimicrob Agents Chemother 1996;40:1657-1664).

Dr. R.T. Davey, Jr., of the NIAID and coworkers studied the safety, toxicity, pharmacokinetics and antiretroviral activity of DLV alone and in combination with zidovudine or didanosine or both. Eighty-five HIV positive patients with...

Want to see the full article?

Purchase this article for only $3.00

We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.

Welcome to NewsRx!

Learn more about a six-week, no-risk free trial of AIDS Weekly

Source: AIDS Weekly (1996-08-05)

NewsRx is Social

Top Medical Newsletters

Awards

Best Health/Healthcare Content, 2012
Best Health/Healthcare Content, 2011
Best e-Business Site, 2010
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005

Facts & Stats

NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.

Google 2010 PageRank: #2 Among Top Health News and Media Publications
Google 2010 PageRank: #2 Among Top Science Publications in Biology/Physiology
Google 2010 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
Amazon's Alexa 2010 PageRank: #2 News and Media Site for the Pharmaceutical Industry